Comparison of the immunological and virological responses to cART between HIV-1/O and HIV-1/M patients followed up in France.

IF 3.9 2区医学 Q1 INFECTIOUS DISEASES Journal of Antimicrobial Chemotherapy Pub Date : 2025-01-13 DOI:10.1093/jac/dkae475

Guillemette Unal, Rémonie Seng, Elodie Alessandri-Gradt, Lorraine Plessis, Mathilde Ghislain, Cécile Goujard, Marie Leoz, Jean-Christophe Plantier, Laurence Meyer

{"title":"Comparison of the immunological and virological responses to cART between HIV-1/O and HIV-1/M patients followed up in France.","authors":"Guillemette Unal, Rémonie Seng, Elodie Alessandri-Gradt, Lorraine Plessis, Mathilde Ghislain, Cécile Goujard, Marie Leoz, Jean-Christophe Plantier, Laurence Meyer","doi":"10.1093/jac/dkae475","DOIUrl":null,"url":null,"abstract":"Background: Therapeutic outcomes for patients infected by genetically divergent HIV-1/O are not well-known due to scarce data and the lack of an appropriate comparison with patients infected by pandemic HIV-1/M. We aimed to compare the immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed in France.Methods: All naïve HIV-1/O subjects initiating cART in France in ANRS-ORIVAO study were compared to naïve HIV-1/M subjects initiating cART in ANRS-COPANA cohort. Piecewise linear mixed-effect models and Kaplan-Meier survival curves were used to analyse immunological and virological response to cART overall (65 HIV-1/O versus 279 HIV-1/M), then only in patients initiating 2INTI + 1PI/r.Results: Plasma viral load (pVL) at treatment initiation was 0.6 log10 copies/mL lower in HIV-1/O than in HIV-1/M patients (P = 0.004) in the overall population, but there was no difference in the time to pVL < 200 cp/mL after cART initiation (log rank test, P = 0.57). Meanwhile, baseline CD4 counts were lower in HIV-1/O (median 180/mm3) than HIV-1/M (248/mm3) patients (P = 0.001). At 4 months, the increase in CD4 counts did not differ (P = 0.96) between groups but remained lower in HIV-1/O patients beyond 4 months of treatment (P = 0.04).In PI/r population, baseline pVL was 1 log10 copies/mL lower for HIV-1/O than HIV-1/M patients, leading to significantly faster attainment of pVL < 200 cp/mL (log rank test: P < 0.001); immunological response to cART was similar.Conclusions: HIV-1/O and HIV-1/M immunological and virological responses to cART did not differ when epidemiological characteristics of the patients were taken into account. In France, treating HIV-1/O following HIV-1/M guidelines leads to similar therapeutic outcomes.","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antimicrobial Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jac/dkae475","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Therapeutic outcomes for patients infected by genetically divergent HIV-1/O are not well-known due to scarce data and the lack of an appropriate comparison with patients infected by pandemic HIV-1/M. We aimed to compare the immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed in France.

Methods: All naïve HIV-1/O subjects initiating cART in France in ANRS-ORIVAO study were compared to naïve HIV-1/M subjects initiating cART in ANRS-COPANA cohort. Piecewise linear mixed-effect models and Kaplan-Meier survival curves were used to analyse immunological and virological response to cART overall (65 HIV-1/O versus 279 HIV-1/M), then only in patients initiating 2INTI + 1PI/r.

Results: Plasma viral load (pVL) at treatment initiation was 0.6 log10 copies/mL lower in HIV-1/O than in HIV-1/M patients (P = 0.004) in the overall population, but there was no difference in the time to pVL < 200 cp/mL after cART initiation (log rank test, P = 0.57). Meanwhile, baseline CD4 counts were lower in HIV-1/O (median 180/mm3) than HIV-1/M (248/mm3) patients (P = 0.001). At 4 months, the increase in CD4 counts did not differ (P = 0.96) between groups but remained lower in HIV-1/O patients beyond 4 months of treatment (P = 0.04).In PI/r population, baseline pVL was 1 log10 copies/mL lower for HIV-1/O than HIV-1/M patients, leading to significantly faster attainment of pVL < 200 cp/mL (log rank test: P < 0.001); immunological response to cART was similar.

Conclusions: HIV-1/O and HIV-1/M immunological and virological responses to cART did not differ when epidemiological characteristics of the patients were taken into account. In France, treating HIV-1/O following HIV-1/M guidelines leads to similar therapeutic outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

法国随访的 HIV-1/O 和 HIV-1/M 患者对 cART 的免疫学和病毒学反应的比较。

背景：由于缺乏数据和缺乏与大流行性HIV-1/M感染患者的适当比较，遗传差异型HIV-1/O感染患者的治疗结果尚不清楚。我们的目的是比较在法国随访的HIV-1/O和HIV-1/M患者对cART的免疫学和病毒学反应。方法：将法国所有在ANRS-ORIVAO研究中启动cART的naïve HIV-1/O受试者与在ANRS-COPANA队列中启动cART的naïve HIV-1/M受试者进行比较。分段线性混合效应模型和Kaplan-Meier生存曲线用于分析对cART的总体免疫和病毒学反应（65例HIV-1/O vs 279例HIV-1/M），然后仅用于开始2INTI + 1PI/r的患者。结果：总体人群中HIV-1/O患者治疗开始时的血浆病毒载量（pVL）比HIV-1/M患者低0.6 log10拷贝/mL (P = 0.004)，但达到pVL的时间没有差异。结论：考虑到患者的流行病学特征，HIV-1/O和HIV-1/M对cART的免疫和病毒学反应没有差异。在法国，按照HIV-1/M指南治疗HIV-1/O导致类似的治疗结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Antimicrobial Chemotherapy 医学-传染病学

CiteScore

9.20

自引率

5.80%

发文量

423

审稿时长

2-4 weeks

期刊介绍： The Journal publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, and articles in veterinary medicine likely to have an impact on global health.